Amount of qualified individuals: CDEC mentioned the uncertainty in the number of patients with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are categorized as getting moderate or reasonable illness may have a intense bleeding phenotype, https://zionsvwwx.blogcudinti.com/36152298/the-basic-principles-of-hemgenix